Form 8-K

8-K — HeartSciences Inc.

Accession: 0001213900-26-107238

Filed: 2026-10-06

Period: 2026-10-06

CIK: 0001468492

SIC: 6199 (FINANCE SERVICES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0307802-8k_heart.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED OCTOBER 6, 2026 (ea030780201ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0307802-8k_heart.htm · Sequence: 1

false

0001468492

2026-10-06

0001468492

us-gaap:CommonStockMember

2026-10-06

0001468492

HSCSW:WarrantsMember

2026-10-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): October 6, 2026

HEARTSCIENCES

INC.

(Exact

name of Registrant as Specified in Its Charter)

Texas

001-41422

26-1344466

(State or Other Jurisdiction of

Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

550

Reserve Street, Suite 360

Southlake, Texas

76092

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s

Telephone Number, Including Area Code: (682) 237-7781

n/a

(Former

Name or Former Address, if Changed Since Last Report)

Check the

appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any

of the following provisions:

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock

HSCS

The Nasdaq Stock Market

LLC

Warrants

HSCSW

The Nasdaq Stock Market

LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01. Regulation FD Disclosure.

October 6, 2026, HeartSciences Inc. (the “Company” or “HeartSciences”) issued a press release announcing

that the U.S. Food and Drug Administration has granted 510(k) clearance (K260005) for the Company’s MyoVista® wavECGTM

device as a 12-lead resting electrocardiograph, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K

(this “Current Report”).

previously reported, on June 23, 2026, HeartSciences, Fortitude Mining Holdings, Inc. (“Fortitude”), Fortitude Mining

HoldCo, LLC and Cordis Acquisition, LLC, entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”)

relating to their proposed business combination (the “Proposed Transaction”).

The

information provided in this Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not

be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”),

or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing

of HeartSciences under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless

of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.

Additional

Information and Where to Find It

Communications

related to each of Fortitude and HeartSciences, their respective businesses and the Proposed Transaction may be deemed solicitation material

in respect of the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences filed an amended preliminary proxy

statement on Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”) on October 6, 2026 (the “Preliminary

Proxy Statement”) and may file additional relevant materials with the SEC from time to time. Following the filing of a definitive

proxy statement with the SEC, HeartSciences will mail the definitive proxy statement and a proxy card to each shareholder entitled to

vote at the special meeting relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE

MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION

THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES

AND THE PROPOSED TRANSACTION. COMMUNICATIONS THAT DO NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED

TRANSACTION AND RELATED MATTERS ARE NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF

SUCH MATTERS. The preliminary proxy statement, the definitive proxy statement and other relevant materials in connection with the Proposed

Transaction (when they become available), and any other documents filed by HeartSciences with the SEC, may be obtained free of charge

at the SEC’s website at www.sec.gov. In addition, investors and shareholders may obtain free copies of the documents filed with

the SEC or by sending a request to the HeartSciences Investor Relations Department at investorrelations@heartsciences.com.

NEITHER

THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS

OR FAIRNESS OF THE PROPOSED TRANSACTION OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS

CURRENT REPORT. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Cautionary

Note Regarding Forward-Looking Information

Communications

may contain forward-looking statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking

statements generally can be identified by the use of words such as “aim,” “anticipate,” “expect,”

“plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,”

“goal,” “project,” “potential,” “target,” “objective,” “intend,”

and other words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. All statements

HeartSciences and/or Fortitude make in communications that do not relate to matters of historical fact should be considered forward-looking

statements.

These

forward-looking statements are based on management’s current expectations and assumptions as of the date of such communication

and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially

from those expressed or implied by such statements, which may include, without limitation, the following: the risk that the Proposed

Transaction may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed

Transaction, including obtaining the requisite approval of the HeartSciences’ shareholders; market, macroeconomic, or other conditions

that could adversely affect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies

and the management of a newly public company; risks relating to Fortitude’s operations and business, including the highly volatile

nature of the price of Zcash and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical

uncertainty regarding digital assets generally. Additional factors that may cause actual results to differ materially from those expressed

or implied by the forward-looking statements in such communications are discussed in the Preliminary Proxy Statement, HeartSciences’

2026 Annual Report on Form 10-K, filed with the SEC on July 23, 2026, its Quarterly Report on Form 10-Q for the fiscal quarter ended

July 31, 2026, filed with the SEC on September 14, 2026, and its other reports filed with the SEC from time to time. Readers are cautioned

not to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation

to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required

by applicable law. Any forward-looking statements made in such communications are made as of the date of the communication.

Participants

in the Solicitation

HeartSciences

and Fortitude, their respective directors and executive officers, and certain executive officers of Digital Currency Group, Inc. (“DCG”),

the parent company of Fortitude, may be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders

with respect to the Proposed Transaction. Information regarding the identity of the potential participants, and their direct or indirect

interests in the Proposed Transaction, by security holdings or otherwise, is set forth in the preliminary proxy statement and other materials

that have been or may be filed with the SEC in connection with the Proposed Transaction.

the ordinary course of business, Fortitude currently sells or otherwise monetizes all the digital assets that it mines, including ZEC.

In addition, Fortitude and its affiliates and subsidiaries, including DCG, from time to time sell, pledge or otherwise monetize their

digital asset holdings, including ZEC. The funds received from such sales, pledges, or other monetization activities are used to fund

operating expenses and capital investments, as well as for other purposes, including to hedge exposures and realize investment gains.

Offer or Solicitation

Any

information contained herein is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of

an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation

of any vote or approval in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance

or transfer of securities in any jurisdiction in contravention of applicable law. The Proposed Transaction will be implemented solely

pursuant to the terms and conditions of the Merger Agreement, which contain the full terms and conditions of the Proposed Transaction.

Item

9.01 Financial Statements and Exhibits

(a)

Exhibits

Exhibit

Number

Description

99.1*

Press Release, dated October 6, 2026.

104*

Cover Page Interactive Data File (embedded

within the Inline XBRL document).

* Furnished

herewith.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

HEARTSCIENCES INC.

Date: October 6, 2026

By:

/s/ Andrew

Simpson

Name:

Andrew Simpson

Title:

President, Chief

Executive Officer and Chairman of the Board of Directors

EX-99.1 — PRESS RELEASE, DATED OCTOBER 6, 2026

EX-99.1

Filename: ea030780201ex99-1.htm · Sequence: 2

Exhibit 99.1

HeartSciences Receives FDA 510(k) Clearance for its MyoVista®

wavECGTM Device

Southlake, TX, October 6, 2026 (GLOBE NEWSWIRE) -- HeartSciences

Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”)

company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence

(“AI”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted 510(k) clearance (K260005)

for its MyoVista® wavECGTM device as a 12-lead resting electrocardiograph. The clearance covers the acquisition

and interpretation of ECG signals from adult and pediatric patients in hospitals and healthcare facilities, with interpretive statements

provided to clinicians on an advisory basis. The clearance does not include an AI-ECG algorithm.

As previously reported, HeartSciences separated the FDA submissions

for the MyoVista wavECG device and its impaired cardiac relaxation AI-ECG algorithm following updated guidance published by the

American Society of Echocardiography regarding the assessment of left ventricular diastolic dysfunction. The Company does not intend to

commercialize the device without a cleared AI-ECG algorithm and has made no commitment to, and has no timeline for, commercialization

of the device. The clearance does, however, broaden the potential options available to the Company for the device and its related intellectual

property, which the Company intends to evaluate.

Andrew Simpson, CEO of HeartSciences, said, “This clearance is

the result of several years of work by our clinical, regulatory and engineering teams, and I want to thank them for the quality and persistence

of that effort. Our commercial focus remains on MyoVista Insights, but clearance makes the device and the intellectual property behind

it a more readily realizable asset, and we will take the time to consider the best route to realizing that value.”

Proposed Transaction with Fortitude

The proposed business combination with Fortitude Mining Holdings, Inc.

(“Fortitude”), announced in June 2026 (the “Proposed Transaction”), continues to progress. The Company expects

to close the Proposed Transaction in Q4 calendar 2026, subject to customary closing conditions, including approval by HeartSciences’

shareholders.

About HeartSciences

HeartSciences is a healthcare information technology company advancing

the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™ Platform is a cloud-native,

vendor- and device-agnostic ECG management system designed to modernize ECG workflows and improve clinical efficiency and decision-making.

The platform’s AI-ECG marketplace is designed to deliver AI-ECG algorithms into clinical workflows across a health system’s

existing ECG equipment.

For more information, please visit www.heartsciences.com and follow

HeartSciences on X @HeartSciences.

About Fortitude

Fortitude, currently wholly-owned by Digital Currency Group, Inc. (“DCG”),

is an institutional-scale, vertically integrated venture mining platform operating across the Proof-of-Work ecosystem and anchored in

Zcash. Fortitude pairs self-mining operations with an owned data center footprint, a diversified power portfolio backed by competitive

long-term contracts, and disciplined capital allocation to identify and scale high-conviction opportunities in emerging Proof-of-Work

ecosystems, beginning with its leadership position in the Zcash network. Fortitude is led by an experienced team of operators, capital

markets professionals, and digital asset specialists with a track record of identifying and scaling high-conviction opportunities and

building privacy-preserving digital asset infrastructure.

For more information, visit www.fortitudemining.com and follow

Fortitude on X at @FortitudeCrypto

In the ordinary course of business, Fortitude currently sells or otherwise

monetizes all the digital assets that it mines, including ZEC. In addition, Fortitude and its affiliates and subsidiaries, including DCG,

from time to time sell, pledge or otherwise monetize their digital asset holdings, including ZEC. The funds received from such sales,

pledges, or other monetization activities are used to fund operating expenses and capital investments, as well as for other purposes,

including to hedge exposures and realize investment gains.

Cautionary Note Regarding Forward-Looking Information

This press release may contain forward-looking statements concerning

HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking statements generally can be identified

by the use of words such as “aim,” “anticipate,” “expect,” “plan,” “could,”

“may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,”

“potential,” “target,” “objective,” “intend,” and other words of similar meaning, but

the absence of these words does not mean that a statement is not forward-looking. All statements HeartSciences and/or Fortitude make in

communications that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management’s current

expectations and assumptions as of the date of this press release and are subject to a number of known and unknown risks, uncertainties,

and other factors that could cause actual results to differ materially from those expressed or implied by such statements, which may include,

without limitation, the following: the risk that the Proposed Transaction may not be completed on the anticipated timeline or at all;

the failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining the requisite approval of HeartSciences’

shareholders; market, macroeconomic, or other conditions that could adversely affect either HeartSciences or Fortitude, or the combined

company; risks related to the integration of the two companies and the management of a newly public company; risks relating to Fortitude’s

operations and business, including the highly volatile nature of the price of Zcash and other cryptocurrencies; risks relating to significant

legal, commercial, regulatory and technical uncertainty regarding digital assets generally; risks relating to the commercialization of

MyoVista InsightsTM, including the rate of adoption by healthcare providers and the conversion of agreements into revenue;

and risks relating to the MyoVista wavECG device, including the Company’s ability to realize value from the device and related

intellectual property, and the recoverability of the related inventory. Additional factors that may cause actual results to differ materially

from those expressed or implied by the forward-looking statements in this press release are discussed in HeartSciences’ amended

preliminary proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on October

6, 2026, in connection with the Proposed Transaction (the “Preliminary Proxy Statement”), HeartSciences’ 2026 Annual

Report on Form 10-K, filed with the SEC on July 23, 2026, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended

July 31, 2026, filed with the SEC on September 14, 2026, and its other reports filed with the SEC from time to time. Readers are cautioned

not to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation

to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required

by applicable law. All forward-looking statements are made as of the date of this press release.

Additional Information About the Proposed Transaction and Where

to Find It

This press release may be deemed solicitation material in respect of

the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences has filed the Preliminary Proxy Statement and may

file additional relevant materials with the SEC. Following the filing of a definitive proxy statement with the SEC, HeartSciences will

mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the special meeting relating to the Proposed

Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO)

AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN

THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. THIS PRESS RELEASE

DOES NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS AND IS NOT INTENDED

TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The Preliminary Proxy Statement, the

definitive proxy statement and other relevant materials in connection with the Proposed Transaction (when they become available), and

any other documents filed by HeartSciences with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In

addition, investors and shareholders may obtain free copies of the documents filed with the SEC by sending a request to the HeartSciences

Investor Relations Department at investorrelations@heartsciences.com.

Participants in the Solicitation

HeartSciences and Fortitude, their respective directors and executive

officers, and certain executive officers of DCG may be deemed to be participants in the solicitation of proxies from HeartSciences’

shareholders with respect to the Proposed Transaction. Information regarding the identity of the potential participants, and their direct

or indirect interests in the Proposed Transaction, by security holdings or otherwise, is set forth in the Preliminary Proxy Statement

and other materials have been or may be filed with the SEC in connection with the Proposed Transaction.

No Offer or Solicitation

Any information contained herein is not intended to and does not constitute,

or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell

or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Proposed Transaction

or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

The Proposed Transaction will be implemented solely pursuant to the terms and conditions of the merger agreement, which contain the full

terms and conditions of the Proposed Transaction.

Investor Relations and Media Contacts:

HeartSciences

Integrous Communications

Mark Komonoski

Phone: 877-255-8483

Email: mkomonoski@integcom.us

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 06, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 06, 2026

Entity File Number

001-41422

Entity Registrant Name

HEARTSCIENCES

INC.

Entity Central Index Key

0001468492

Entity Tax Identification Number

26-1344466

Entity Incorporation, State or Country Code

Entity Address, Address Line One

550

Reserve Street

Entity Address, Address Line Two

Suite 360

Entity Address, City or Town

Southlake

Entity Address, State or Province

Entity Address, Postal Zip Code

76092

City Area Code

682

Local Phone Number

237-7781

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Common Stock

Trading Symbol

HSCS

Security Exchange Name

NASDAQ

Warrants

Title of 12(b) Security

Warrants

Trading Symbol

HSCSW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=HSCSW_WarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: